The apparent impact of CYP2C19 genotype in treatment response to citalopram and escitalopram in depression, together with the observations of differences in CYP2C19 pharmacogenetics of bipolar depressed patients, warrants further exploration. This evidence concerns the gene CYP2C19 and depressive symptom measurement.